Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has granted 6,238 restricted stock units to eight new non-executive employees under its 2024 Inducement Plan. The grants, approved by the Compensation Committee on September 2, 2025, were made in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest over four equal annual installments, contingent upon continued employment. These equity awards are specifically designed for new hires who were not previously Praxis employees, serving as employment inducements.
Praxis Precision Medicines (NASDAQ: PRAX), una società biofarmaceutica in fase clinica specializzata nei disturbi del sistema nervoso centrale, ha assegnato 6.238 unità di azioni vincolate a otto nuovi dipendenti non dirigenti nell'ambito del suo Piano di Induzione 2024. Le assegnazioni, approvate dal Comitato per la Remunerazione il 2 settembre 2025, sono state effettuate in conformità alla Nasdaq Listing Rule 5635(c)(4).
Le unità di azioni vincolate matureranno in quattro rate annuali uguali, subordinatamente al mantenimento del rapporto di lavoro. Questi premi azionari sono pensati specificamente come incentivi per nuove assunzioni che non erano precedentemente dipendenti di Praxis.
Praxis Precision Medicines (NASDAQ: PRAX), una compañía biofarmacéutica en fase clínica centrada en los trastornos del sistema nervioso central, ha concedido 6.238 unidades de acciones restringidas a ocho nuevos empleados no ejecutivos bajo su Plan de Inducción 2024. Las concesiones, aprobadas por el Comité de Compensación el 2 de septiembre de 2025, se realizaron de conformidad con la Norma de Cotización de Nasdaq 5635(c)(4).
Las unidades de acciones restringidas se consolidarán en cuatro pagos anuales iguales, condicionados a la continuidad del empleo. Estas otorgaciones de capital están diseñadas específicamente como incentivos para contrataciones que no eran previamente empleados de Praxis.
Praxis Precision Medicines (NASDAQ: PRAX), 중추신경계 질환에 주력하는 임상 단계의 바이오제약사인 이 회사는 2024년 유인(Inducement) 플랜에 따라 신규 비임원 직원 8명에게 6,238개의 제한부 주식 단위를 부여했습니다. 해당 부여는 보상위원회가 2025년 9월 2일에 승인했으며, Nasdaq 상장규정 5635(c)(4)를 준수해 이루어졌습니다.
이 제한부 주식 단위는 4년간 매년 동일한 비율로 나눠 베스팅되며, 계속 근무하는 것을 조건으로 합니다. 이러한 주식 보상은 기존에 Praxis 직원이 아니었던 신규 채용자에 대한 고용 유인책으로 설계되었습니다.
Praxis Precision Medicines (NASDAQ: PRAX), une société biopharmaceutique en phase clinique spécialisée dans les troubles du système nerveux central, a attribué 6 238 unités d'actions restreintes à huit nouveaux employés non cadres dans le cadre de son Plan d'Induction 2024. Les attributions, approuvées par le comité de rémunération le 2 septembre 2025, ont été effectuées conformément à la règle de cotation Nasdaq 5635(c)(4).
Les unités d'actions restreintes deviendront acquises en quatre versements annuels égaux, sous réserve de la poursuite de l'emploi. Ces attributions en actions sont conçues spécifiquement comme des incitations à l'embauche pour des personnes qui n'étaient pas précédemment employées par Praxis.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Erkrankungen des zentralen Nervensystems, hat im Rahmen seines Inducement-Plans 2024 6.238 Restricted Stock Units an acht neue nichtleitende Mitarbeiter gewährt. Die Zuteilungen wurden vom Vergütungsausschuss am 2. September 2025 genehmigt und erfolgten in Übereinstimmung mit Nasdaq Listing Rule 5635(c)(4).
Die Restricted Stock Units werden in vier gleichen jährlichen Raten unverfallbar, vorbehaltlich fortgesetzter Beschäftigung. Diese Aktienzuteilungen sind speziell als Anreiz für neu eingestellte Mitarbeitende gedacht, die zuvor nicht bei Praxis beschäftigt waren.
- None.
- None.
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on September 2, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 6,238 shares of its common stock to eight new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Contacts: Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
What type of equity awards did Praxis Precision Medicines (PRAX) grant to new employees?
How will the PRAX restricted stock units vest for new employees?
Why did Praxis Precision Medicines issue these stock grants?
What is Praxis Precision Medicines' main business focus?
